These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23744798)

  • 1. Baseline dependency of nicotine's sensory gating actions: similarities and differences in low, medium and high P50 suppressors.
    Knott V; de la Salle S; Smith D; Phillipe T; Dort H; Choueiry J; Impey D
    J Psychopharmacol; 2013 Sep; 27(9):790-800. PubMed ID: 23744798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of nicotine on P50 amplitude, its gating, and their neural sources in low and high suppressors.
    Knott VJ; Fisher DJ; Millar AM
    Neuroscience; 2010 Oct; 170(3):816-26. PubMed ID: 20643194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of nicotine on the amplitude and gating of the auditory P50 and its influence by dopamine D2 receptor gene polymorphism.
    Knott V; Millar A; Fisher D; Albert P
    Neuroscience; 2010 Mar; 166(1):145-56. PubMed ID: 19961902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDP-choline: effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression.
    Knott V; Smith D; de la Salle S; Impey D; Choueiry J; Beaudry E; Smith M; Saghir S; Ilivitsky V; Labelle A
    J Psychopharmacol; 2014 Dec; 28(12):1095-108. PubMed ID: 25315828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of COMT genotype on sensory gating and its modulation by nicotine: Differences in low and high P50 suppressors.
    de la Salle S; Smith D; Choueiry J; Impey D; Philippe T; Dort H; Millar A; Albert P; Knott V
    Neuroscience; 2013 Jun; 241():147-56. PubMed ID: 23535252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
    Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
    J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of acute exogenous melatonin on P50 suppression in healthy male volunteers stratified for low and high gating levels.
    Ucar E; Lehtinen EK; Glenthøj BY; Oranje B
    J Psychopharmacol; 2012 Aug; 26(8):1113-8. PubMed ID: 22331175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia.
    Hong X; Chan RC; Zhuang X; Jiang T; Wan X; Wang J; Xiao B; Zhou H; Jiang L; Weng B
    Schizophr Res; 2009 Mar; 108(1-3):151-7. PubMed ID: 19106034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The moderating role of the dopamine transporter 1 gene on P50 sensory gating and its modulation by nicotine.
    Millar A; Smith D; Choueiry J; Fisher D; Albert P; Knott V
    Neuroscience; 2011 Apr; 180():148-56. PubMed ID: 21315807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.
    Zhang XY; Liu L; Liu S; Hong X; Chen DC; Xiu MH; Yang FD; Zhang Z; Zhang X; Kosten TA; Kosten TR
    Am J Psychiatry; 2012 Sep; 169(9):974-81. PubMed ID: 22952075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensory gating and source analysis of the auditory P50 in low and high suppressors.
    Knott V; Millar A; Fisher D
    Neuroimage; 2009 Feb; 44(3):992-1000. PubMed ID: 19007892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of auditory deviance detection by acute nicotine is baseline and deviant dependent in healthy nonsmokers: a mismatch negativity study.
    Knott V; Impey D; Philippe T; Smith D; Choueiry J; de la Salle S; Dort H
    Hum Psychopharmacol; 2014 Sep; 29(5):446-58. PubMed ID: 25196041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The separate and combined effects of monoamine oxidase inhibition and nicotine on P50 sensory gating.
    Smith DM; Fisher D; Blier P; Illivitsky V; Knott V
    Psychopharmacology (Berl); 2015 Jun; 232(11):1911-20. PubMed ID: 25466703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic modulation of the P50 auditory-evoked potential in a computer model of the CA3 region of the hippocampus: its relationship to sensory gating in schizophrenia.
    Moxon KA; Gerhardt GA; Adler LE
    Biol Cybern; 2003 Apr; 88(4):265-75. PubMed ID: 12690485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials.
    Siegel SJ; Maxwell CR; Majumdar S; Trief DF; Lerman C; Gur RE; Kanes SJ; Liang Y
    Neuroscience; 2005; 133(3):729-38. PubMed ID: 15908134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic effects on auditory sensory gating in schizophrenia patients.
    Sánchez-Morla EM; Santos JL; Aparicio A; García-Jiménez MA; Villanueva C; Martínez-Vizcaíno V; Arango C
    Eur Neuropsychopharmacol; 2009 Dec; 19(12):905-9. PubMed ID: 19833483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential sensory gating functions between smokers and non-smokers among drug-naive first episode schizophrenic patients.
    Chen XS; Li CB; Smith RC; Xiao ZP; Wang JJ
    Psychiatry Res; 2011 Aug; 188(3):327-33. PubMed ID: 21216472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatment.
    Oranje B; Aggernaes B; Rasmussen H; Ebdrup BH; Glenthøj BY
    Schizophr Bull; 2013 Mar; 39(2):472-80. PubMed ID: 22241164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study.
    Winterer G; Gallinat J; Brinkmeyer J; Musso F; Kornhuber J; Thuerauf N; Rujescu D; Favis R; Sun Y; Franc MA; Ouwerkerk-Mahadevan S; Janssens L; Timmers M; Streffer JR
    Neuropharmacology; 2013 Jan; 64():197-204. PubMed ID: 22766391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study.
    Waldo MC; Woodward L; Adler LE
    Psychiatry Res; 2010 Jan; 175(1-2):179-80. PubMed ID: 19959243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.